Biopharmaceutical Contract Manufacturing Market is About to Reach US$ 2,200 Mn by the end of 2027

Posted on 2017-11-06 by Mark Hub in Healthcare // 0 Comments

Albany, US, 2017-Nov-06 — /EPR Network/ —A new report added to the repository of Market Research Reports Search Engine “Biopharmaceutical Contract Manufacturing Market: Oncology Segment by Therapeutic Area to Dominate the Global Market Through 2027: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027” is a comprehensive repository of information, providing market share, size, and forecast.

Get Free Sample Report@ https://www.mrrse.com/sample/3556

The global biopharmaceutical contract manufacturing market is expected to grow 2.7x by 2027 as compared to that in 2017. Several factors are likely to influence this growth. There has been a steady increase in the number of biopharmaceuticals in the pipeline. This is anticipated to boost revenue growth of the global biopharmaceutical contract manufacturing market. Further, development of advanced process technology and scale-up expertise is another key market growth driver. Adoption of a one-stop-shop service delivery model and optimisation of capacity and utilisation rates to cater to complex requirements are key opportunity areas for companies operating in the global biopharmaceutical contract manufacturing market. Biopharmaceutical companies are focussed on the outsourcing of biomanufacturing owing to the involvement of high capital investment in the establishment of biologics manufacturing units. This has elevated the demand for CMOs in the global biopharmaceutical contract manufacturing market.

The global biopharmaceutical contract manufacturing market is also likely to witness a few trends in the coming years. Use of high density cell culture and perfusion technology as well as single-use and continuous processing technologies in mammalian biomanufacturing will gain traction in the near future. The global market for biopharmaceutical contract manufacturing is not devoid of challenges. Limited capacity in CMOs for large volume biopharmaceuticals coupled with a high capital investment required for equipment, technology, and expertise is likely to stifle revenue growth of the global biopharmaceutical contract manufacturing market during the course of the forecast period.

View Full Report At@ https://www.mrrse.com/biopharmaceutical-contract-manufacturing-market

Oncology to lead the global biopharmaceutical contract manufacturing market by therapeutic area

Of the various therapeutic areas in the global biopharmaceutical contract manufacturing market, the Oncology segment is anticipated to remain dominant throughout the forecast period, with revenues in excess of US$ 1,000 Mn by 2017 end and likely to reach a market valuation of more than US$ 3,800 Mn by the end of the forecast period in 2027. This is reflective of a CAGR of 13.1% in terms of value – the highest among all the segments by therapeutic area in the global biopharmaceutical contract manufacturing market. Autoimmune Disease is the second biggest segment in terms of therapeutic area – estimated to reach a market valuation in excess of US$ 2,200 Mn by the end of 2027, up from more than US$ 880 Mn expected to be recorded by the end of 2017. This denotes a CAGR of 10.0% in terms of value during the period of forecast. The Oncology segment is expected to be the most lucrative segment by therapeutic area over the forecast period, with a market attractiveness index of 2.5.

Oncology to remain the largest segment by therapeutic area across the various regional markets

In the North America biopharmaceutical contract manufacturing market, the Oncology segment by therapeutic area is anticipated to remain dominant with a market value of about US$ 1,208 Mn expected to be recorded by the end of 2027, with a CAGR of 12.2%. The Autoimmune Disease therapeutic area segment is estimated to reach a market valuation of US$ 700 Mn in the North America biopharmaceutical contract manufacturing market by the end of 2027. In the Western Europe regional market, the Oncology segment will witness the highest growth rate of 13.2% to reach a market valuation in excess of US$ 950 Mn by the end of the forecast period. Oncology is anticipated to be the largest and most dominant segment in the APEJ biopharmaceutical contract manufacturing market, with revenues just under US$ 260 Mn expected to be recorded by the end of 2017 and likely to increase to about US$ 1,022 Mn by the end of 2027, registering a CAGR of 14.7% during the forecast period.

Enquire About this Report@ https://www.mrrse.com/enquiry/3556

About MRRSE

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Matched content

Editor’s pick